MediSieve

Novel Biotech dual-platform: therapeutic and drug-delivery

General Information
Company Name
MediSieve
Founded Year
2015
Location (Offices)
London, United Kingdom +1
Founders / Decision Makers
Number of Employees
13
Industries
Biotechnology, Health Care, Health and Wellness +1
Funding Stage
Series Unknown
Social Media

MediSieve - Company Profile

MediSieve is a London-based biotech startup that has developed Magnetic Haemofiltration, a groundbreaking platform therapy capable of removing specific substances from patients' bloodstream. This technology can be utilized as a direct treatment, to enhance the safety and effectiveness of other therapies, or to enable personalized medicine. The potential markets for this product span across oncology, infectious diseases, auto-immune diseases, poisoning, and drug overdose, representing multi-billion-dollar opportunities. Notably, Magnetic Haemofiltration has demonstrated rapid and effective removal of IL-6 from human plasma.

The company, established in 2015, has already raised £4M in equity funding and secured over £4M in non-dilutive grants. Currently, they are seeking an additional £8M at Series A to support pivotal clinical trials and regulatory approvals, with eligibility for EIS. MediSieve's notable recognition includes features in leading media publications such as the Sunday Telegraph, Daily Mail, and Wired Magazine. Moreover, the company has achieved success in various startup competitions and its founder, George Frodsham, has been honored with the BBSRC Innovator of the Year and MIT Innovators Under 35 awards.

Notably, the latest £1.60M grant investment in June 2021 was secured from UK Research and Innovation. The technology has completed pre-clinical validation, including animal studies, and is projected to commence clinical studies in Q2 2022. As a result of its innovative approach and potential, MediSieve presents an exciting opportunity for venture capital investors looking to participate in the biotechnology, health care, medical devices, and health and wellness industries.

Taxonomy: blood purification, magnetic bead technology

Funding Rounds & Investors of MediSieve (10)

View All
Funding Stage Amount No. Investors Investors Date
Grant £1.60M 1 23 Jun 2021
Venture Round £1.80M 1 23 Jun 2021
Grant £1.56M 3 Biomedical Catalyst Fund 30 Jan 2019
Series A £1.75M 2 Wharton Asset Management Company Limited 04 Jun 2018
Grant £150.00K 1 National Institute of Health Research 08 Feb 2018

View All 10 Funding Rounds

Latest News of MediSieve

View All

No recent news or press coverage available for MediSieve.

Similar Companies to MediSieve

View All
UKCA and Partners LLP - Similar company to MediSieve
UKCA and Partners LLP UKCA and Partners has been eminent in providing legal advisory, transactional and advocacy services.
AELIS FARMA - Similar company to MediSieve
AELIS FARMA A clinical stage biotech company opening a new frontier in pharmacology
OIRRC - Similar company to MediSieve
OIRRC OIRRC specializes in providing ocular image acquisition and interpretation services for multicenter clinical trials